红状腺原生细胞的表观遗传重编程:增强癌症免疫疗法的洞察力
Zi-Zhan Li1, Xuan-Yu Su1, Cheng-Ke Zhou1
1The State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Frontier Science Center for Immunology and Metabolism, Taikang Center for Life and Medical Sciences, Wuhan University, Wuhan, 430079, China.
International journal of biological sciences
|February 16, 2026
概括
瘤微环境 (TME) 中的红色素原生细胞 (EPC) 可以通过表观遗传重新编程,从而导致癌症免疫疗法耐药性. 针对这种重新编程可能会提高治疗的有效性.
科学领域:
- 癌症免疫学 癌症免疫学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 瘤微环境研究研究
背景情况:
- 癌症免疫疗法提供了更好的结果,但由于反应率较低而面临局限性.
- 了解瘤微环境 (TME) 是克服抗癌疗法的关键.
- 在TME中,红色素原生细胞 (EPC) 的重编程是免疫疗法耐药性的新兴机制.
研究的目的:
- 审查TME中EPCs的表观遗传重编程.
- 探索重编程EPC与瘤/免疫细胞之间的相互作用.
- 评估针对EPC的表观遗传药物,以加强免疫疗法.
主要方法:
- 文献综述侧重于TME内EPC重编程中的表观遗传机制.
- 分析EPC与瘤和免疫细胞的交叉声调.
- 评估涉及EPCs表观遗传调制的治疗策略.
主要成果:
- 在TME中,EPCs经历表观遗传重编程,影响免疫逃避.
- 重编程的EPC与免疫细胞相互作用,导致免疫疗法耐药性.
- 在EPC中的表观遗传修饰代表了潜在的治疗点.
结论:
- 对EPCs的表观遗传重编程是癌症免疫疗法耐药性的重要因素.
- 针对EPC表观遗传变化的治疗有望提高免疫疗法的疗效.
- 对逆转病态EPC重编程的进一步研究对于推进癌症治疗至关重要.
相关概念视频
Somatic to iPS Cell Reprogramming
2.7K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.7K
Methods of Nuclear Reprogramming
2.2K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
2.2K
Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Introduction to Nuclear Reprogramming
2.3K
Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
2.3K
Chromatin Modification in iPS Cells
2.2K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
2.2K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K


